Discovery of piperazic acid peptide deformylase inhibitors with in vivo activity for respiratory tract and skin infections.
Spletstoser, J.T., Dreabit, J., Knox, A.N., Benowitz, A., Campobasso, N., Ward, P., Cui, G., Lewandowski, T., McCloskey, L., Aubart, K.M.(2019) Bioorg Med Chem Lett 29: 2410-2414
- PubMed: 31160176 
- DOI: https://doi.org/10.1016/j.bmcl.2019.05.028
- Primary Citation of Related Structures:  
6OW2, 6OW7 - PubMed Abstract: 
The discovery of a novel series of peptide deformylase inhibitors incorporating a piperazic acid amino acid found in nature is described. These compounds demonstrated potent in vitro enzymatic potency and antimicrobial activity. Crystal structure analysis revealed the piperazic acid optimized a key contact with the PDF protein that accounted for the increased enzymatic potency of these compounds. We describe lead optimization of the P3' region of the series that resulted in a compound with good potency against three target organisms. One molecule showed in vivo efficacy in a rat respiratory infection model but ultimately did not meet candidate progression criteria.
Organizational Affiliation: 
GlaxoSmithKline, 1250 S. Collegeville Rd., Collegeville, PA 19426, USA. Electronic address: jared.t.spletstoser@gsk.com.